Clinical trials: Severe Acute Respiratory Syndrome (SARS) Pneumonia
SARS CoV 2 Infection, Alveolar; Injury
The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19
COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the…
- Conditions
- SARS CoV 2 Infection, Alveolar; Injury, Children, Pneumonia, Viral
- Trial name
- NCT05619640
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Haseki Training and Research Hospital
SARS-CoV-2
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation…
- Trial name
- NCT05894525
- Where
- Japan
- Volunteers
- 8,844 people
- Sponsor
- ModernaTX, Inc.
Multiple Osteochondroma, Osteogenesis Imperfecta
Resilience and Coping in a Rare Skeletal Disease Population to Face Coronavirus (COVID-19) Outbreak Distress: a Longitudinal Study
In the COVID-19 outbreak context, people living with rare diseases have been highly troubled with anxiety, loneliness, and depression.
- Conditions
- Multiple Osteochondroma, Osteogenesis Imperfecta, Ollier Disease, Maffucci Syndrome
- Trial name
- RELOAD (NCT04844697)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Istituto Ortopedico Rizzoli
SARS-CoV Infection, Interferon
The Containing Coronavirus Disease 19 (COVID-19) Trial
In recent months severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has emerged as a novel human pathogen and, susceptibility amongst humans is presumed to be universal.
- Conditions
- SARS-CoV Infection, Interferon, Covid19
- Trial name
- ConCorD-19 (NCT04552379)
- Testing
- Peginterferon beta-1a
- Where
- Chile
- Volunteers
- 1,173 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
COVID-19
COVID-19 PrEP HCW HCQ Study
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04354870
- Testing
- Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- NYU Langone Health
COVID, Covid-19
Trial of Combination Therapy to Treat COVID-19 Infection
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
- Conditions
- COVID, Covid-19, Corona Virus Infection, Coronavirus Infection
- Trial name
- NCT04482686
- Testing
- Ivermectin, Doxycycline Hcl, Zinc
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- ProgenaBiome
Covid19, Surgery
Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery
We have herein analysed the patients admitted to our Department that underwent serologic tests for SARS-CoV-2 either by Ab or RT PCR, to estimate the prevalence of COVID-19 in the setting of a non-dedicated COVID-19 hospital and…
- Conditions
- Covid19, Surgery, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- NCT04480580
- Testing
- SARS-CoV-2 Ab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Cagliari
COVID-19
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects…
- Trial name
- NCT05386472
- Testing
- nirmatrelvir, ritonavir
- Where
- 13 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pfizer
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19 Related Health and Infection Control Practices Among Dentists
As dentists begin reopening their practices during a global pandemic, the risk of COVID-19 infection that dentists face in providing dental care remains unknown.
- Trial name
- NCT04423770
- Testing
- No intervention
- Where
- United States
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- American Dental Association
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
SARS-CoV Infection, Covid19
KIDney Injury in Times of COVID-19 (KIDCOV)
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable.
- Conditions
- SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury
- Trial name
- KIDCOV (NCT04705766)
- Testing
- Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Covid19, COVID-19
Tocilizumab in Coronavirus-19 Positive Patients
This is a cohort study of COVID-19 patients with hyperinflammation. It aims to determine the impact of adjunctive Tocilizumab (TCZ) to standard of care on the reduction of hyperinflammation-related mortality in COVID-19.
- Conditions
- Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus
- Trial name
- NCT04423042
- Testing
- Tocilizumab
- Volunteers
- 30 people
- Sponsor
- University of Calgary
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
SARS-CoV Infection, COVID-19
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19
There is emerging evidence that patients with SARS-CoV-2 are affected by increased coagulopathy, including in the most advanced forms, a fully blown disseminated intravascular coagulation, leading to multi organ failure (MOF).
- Trial name
- CONVINCE (NCT04516941)
- Testing
- Edoxaban Tablets, Colchicine Tablets
- Where
- 5 sites in Belgium, Italy and 1 more
- Volunteers
- 60 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19, SARS-CoV Infection
Glycine Supplement for Severe COVID-19
This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and biochemical parameters, in…
- Conditions
- COVID-19, SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia
- Trial name
- NCT04443673
- Testing
- Glycine
- Where
- Mexico
- Volunteers
- 59 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
COVID-19
Bioaerosol Sampling Device (BSD) Clinical Study
The goal of this clinical trial is to learn about the bioaerosol sampling device (BSD) and how it can sample patient bioaerosols (breath) and patient's nares for the detection of COVID-19 viral particles in patients seeking to be…
- Trial name
- NCT06047067
- Where
- 6 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Cantor BioConnect, Inc.
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and…
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Trial name
- NCT05004181
- Testing
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7)
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Follow-up of Covid-19 Long Term Sequelae
The protocol, in accordance with the objectives of ORCHESTRA project - Work Package 2, aims at investigating the characteristics and determinants of COVID-19 long-term sequelae.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05097677
- Testing
- Not applicable (observational study)
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 7,599 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona